Email updates

Keep up to date with the latest news and content from BMC Pharmacology and Toxicology and BioMed Central.

Open Access Highly Accessed Research article

Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

Oliver Löwenstein, Petra Leyendecker*, Eberhard A Lux, Mark Blagden, Karen H Simpson, Michael Hopp, Björn Bosse and Karen Reimer

BMC Clinical Pharmacology 2010, 10:12  doi:10.1186/1472-6904-10-12

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Minor Correction

Petra Leyendecker   (2010-12-07 15:56)  Mundipharma Research GmbH & Co. KG email

After the publication of this work it was brought to our attention that on page 4, in the first paragraph of Results section, the values for the rates of discontinuation of the two treatment groups have been transposed in error. The sentence should read: "Similar rates of study drug discontinuation were observed in the two treatment groups: 16.3 and 13.7%, respectively, in the oxycodone PR and the oxycodone PR/naloxone PR groups."

In Figure 3 on page 7, the symbols used in the key for the graph have been erroneously transposed. The correct key should be the black circle and solid line symbol for “Oxycodone PR/naloxone PR”, and the black diamond and dashed line symbol for “Oxycodone PR”

We regret any confusion that these errors may have caused, and thank our colleagues for bringing it to our attention.

Competing interests

None

top

Post a comment